Cagrilintide's dosing interval and the pharmacokinetics behind it

Post #12 is right about the mechanism and I think understates the practical bit.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

Coming back to post #14, because the follow-up matters more than the original answer.

The pharmacokinetics support weekly dosing comfortably. What the pharmacokinetics do not tell you is the tolerable escalation rate, and that is the practical constraint in every published protocol.

Understood, and I withdraw the assumption I opened with.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

A qualification I should have led with rather than closed on.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

Posted with less confidence than the sentence structure implies.

Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.

That is the honest state of it as of this week.

This is the sort of exchange that makes the archive worth searching.

Post #19 put the caveat in the right place and I want to underline it.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

I checked the source rather than the summary, and they differ.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

I would put the burden of proof on the interesting explanation, not the dull one.

The arithmetic in post #23 is right; the assumption feeding it is the part to check.

The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

That is what the documentation says. What happens in practice is usually close.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

Marking that as an opinion rather than a finding.

Post #27 describes the usual case. This is about the unusual one.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

Adding the measurement that post #27 says would settle it.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

The conclusion is tentative; the arithmetic underneath it is not.